ConvaTec Group (LON:CTEC – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Jefferies Financial Group in a research note issued on Monday,Digital Look reports. They currently have a GBX 300 price objective on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 49.25% from the company’s previous close.
A number of other equities analysts have also weighed in on the company. Berenberg Bank reiterated a “buy” rating and issued a GBX 340 price target on shares of ConvaTec Group in a research report on Tuesday, April 21st. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 315 price target on shares of ConvaTec Group in a research report on Wednesday, April 8th. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 315 price target on shares of ConvaTec Group in a research report on Wednesday, March 11th. JPMorgan Chase & Co. decreased their price target on ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating for the company in a research report on Friday, May 22nd. Finally, UBS Group restated a “buy” rating and set a GBX 375 price objective on shares of ConvaTec Group in a research report on Monday, May 18th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of GBX 306.
View Our Latest Stock Report on ConvaTec Group
ConvaTec Group Trading Down 2.4%
Insider Buying and Selling
In other ConvaTec Group news, insider Jonny Mason acquired 50,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was purchased at an average cost of GBX 201 per share, for a total transaction of £100,500. Insiders own 0.98% of the company’s stock.
ConvaTec Group Company Profile
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Read More
- Five stocks we like better than ConvaTec Group
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
